Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TSX perhaps or the Safe Banking Act lets us uplift in US - I’d prefer NASDAQ.
So we should anticipate this drop again in Jan and Feb when more shares freed up. We should urge TRUL to get on a more liquid exchange before then or we get played again.
Fingers crossed.
Me too - still waiting for confirmation tomorrow if this is the bottom.
Will it turn soon with insiders freed to sell at .50 and .05 cent cost basis? Could keep coming in lower. I want to put more in but I did a little yesterday. Will we see 6?
John - did you read the twitter analysis from Snap below? Pretty good DD and unfortunate for the pressure on the stock as people with cheap paper cash out. Valuation under 8 for this rev and earnings and potential is amazing.
I am also long here and freed up quite a bit the past few weeks to see where this settles. (Actually I wondered if it would run post earnings). So I will watch and wait - amazing valuations at this SP with our current earnings and guidance. I really hope Safe Banking Act passes and that gives ok to US exchanges to list MSOs this fall.
At what point do they have enough cash and realize the shares they still hold are going to be worth 3x in a year ... could be soon. Could be $6? I wonder what the factors are.
That is amazing. Really good to know and good analysis by the guy on Twitter. Unfortunate for us. Will be interesting to see when / how this slows and or stops.
I would love my TRUL to be 9B. And I also think Liberty is undervalued. As is TRUL
How do you get Trulieve at 9 billion?
Brutal in near term. Need a better exchange and more awareness.
Wolf- I am long both, been in CVSI since less than $1 and in CW since it came to market, and overweight CBD in CVSI due to value. I know that I do not know enough to be certain of the future path of CBD and like both companies for somewhat different reasons. Both have challenges too. Therefore the last couple of weeks on the boards have been doubly annoying for me. I wish everyone well you understand :)
The uncertain regulatory environment is the key to how CWBHF can make the claim to the guidance range. If FDA comes out Sept 1 with clear and easy to manage interim regulations, then we could have 3-4 explosive months and maybe (likely) get to some great numbers. But I think our run rate could only get near the low end of the guidance if FDA is slow, delays until 2020 etc and leaves all CBD as status quo for the fall and winter. So I don't see it as false guidance at all, just pinned on FDA (as the whole CBD industry is in the near term).
When is annual meeting?
Agreed - thanks KF.
Funny - Cabo is relaxing and tacos are delicious, but together Cabos+Tacos is annoying and bitter. Life works in mysterious ways.
Incorrect. Did you read the recent announcement about 10mil coming on this July? Then 10 mil more in Jan I think?
We don’t know what percentage of the 250k each day is unlocked shares from insiders being sold in small lots right? Is it 150k per day or 200k per day recently? So 5-6 days for 1 mil of these newly unlocked shares to trade; then times 10 to account for the remote possibility all 10 mil hit the market. So 2 months to work through the unlock? Someone who understands the flow of how unlocked shares would be traded can chime in - this is beyond me and just my speculation.
The main reason is the 10 mil share flowing to market since July 25 is my guess. With our super low volume that is a big pig to digest. Maybe work it through by mid-Sept give our average daily volume? I think this heavy pig is what is Making this big TCNNF python look sluggish for a while.
Basis Around mid10 now. Is this going to come all the way back to close green today? I’d like that.
Today bit hard after a great report. But I think I will be happy buying a little more today in the high 8s. My top play now by far. Go Trulieve
I saw the Healing Place cost. 14m was just the license I think. The main thing we bought it appears.
Word.
Snap - looking forward to your analysis - should be enjoyable
Astounding loss (over a Billion) by Canopy following the previous day Tilray garbage... the true leaders running profitable businesses are CW CVSI and TCNNF.
That is an astounding loss by Canopy. All the more impressed with TCNNF discipline and plan. Go Trulieve
They talked a lot about pet category on the call this AM. Interesting route - maybe we will partner with a reputable pet food co
Honest question Darth: could it be that Dowling is just being practical and simply following the political realities of what will be politically expedient to approve by saying industrial hemp? Just using the same language that is written in the Farm Bill? ( I truly appreciate the depth you and others know about the technicals on cannabis and hemp- much much more than me and I am not going to argue) but I’m just not sure it’s a campaign against others which would / could have many downside negative effects for his own company. What’s his motivation for going against the entire industry that stands to make him rich? Occam says shave simply you understand.
VFF ceo on MadMoney tonight - not Kim
I saw this for CGC. For sake of the sector, hope the best it. “consensus EPS Estimate is -$0.31 and the consensus Revenue Estimate is $84.62M”
By the way - a high end total Q for Trulieve puts us #2 in world behind CGC with 1/20th of its market cap?
CWEB missed expectations however. I think TCNNF will crush.
A little Run may be starting ...
Agreed - and cash burn seemed aggressive at first glance. I hope the call explains the investments - new facilities, but also the vagaries and costs of farming. I doubt they get treated as rough as CVSI though - my WAguess 10% down, we'll see how institutional money on TSX helps vs our OTC beatings... Will be nice when CVSI is given a similar multiple.
Super: trying for a rational correspondence on this board with any of "the three amigos of fear and bs" (V, BKK/MontanaJack, iblow) is not a good idea you understand.
CVSI is my second largest behind TRUL/TCNNF and CWBHF third but pretty far down exactly because of the valuation issue you mention. I think I will (eventually) have more leverage with CVSI. I sold about a third of CW after their recent run up and bought more of my top two at discount.
CW earnings just posted .02 EPS, 75% gross margins, and 45% YoY comp looks very similar to CVSI in my opinion. But headlines read miss. I think this is also a good Q as was CVSI given the CBD market issues. I'm in them both and I'd like CW report to be treated more fairly on TSX, but my feeling is a beating today but not as deep and rapid as CVSI last week. Will be interesting to compare.
LABS/MEDIF and VFF did very well. I agree that I think it sets up TCNNF well when bigger money is looking for most Net profitable and future potential
Fast - do you know if Piper covers other OTC stocks?
Good news on Piper. superTrades you asked for this, right? Confirms your recent buys?
Letter from Dowling just out: https://ir.cvsciences.com/press-releases/detail/125/cv-sciences-inc-ceo-issues-letter-to-shareholders
Dear Shareholders,
Last week we issued our second quarter results, reporting the highest quarterly revenue in our company’s history, continuing a streak of 14 consecutive quarters of sequential revenue growth. This consistent growth is a reflection of the strength of the PlusCBD™ Oil brand and our growing distribution across retail channels. Year to date, we have more than doubled the number of retail doors where PlusCBD™ Oil products are carried, and we continue to enjoy a strong pipeline of new distribution opportunities. The fundamentals of our business are strong and our opportunity grows daily as consumer demand for hemp-based CBD products continues to expand at a rapid rate. We are proud of our second quarter results, but like you, we are disappointed by the market’s reaction. We pride ourselves on giving comprehensive quarterly updates, and our discussion of increased competition reflects what we see in our business today. But, as I noted on our second quarter conference call, incremental competition may lead to choppy quarter to quarter results. However, it does not detract from the rapidly growing market opportunity and expanding distribution, which along with our continued investments in our brand and industry leading quality, are the foundation of our long-term growth trajectory.
We have worked hard this year to further strengthen our company and fully leverage the power of the PlusCBD™ Oil brand. We have added key leadership talent, invested in systems to strengthen our business processes, broadened our product offering, expanded our supply chain to source domestic hemp and signed a lease to expand our production and warehousing capacity by five-fold. We are investing in consumer research to support a brand refresh and best position our brand for growth. We are also accelerating our Direct-to-Consumer tactics, including a redesign of our PlusCBD™ Oil consumer site and adding tools to accelerate online sales. Additionally, we are actively pursuing new distribution channels to complement our core natural product retailer channel and growing distribution into the food, drug and mass channels. We have a great story to tell…to consumers, to retailers and to investors.
As I recently told CBD Today, “To really compete, you have to have a brand that is respected and trusted, and then you have to have scale. If you don’t have those two things, you’re not going to be able to compete, and we have both. We are the only company with true fundamentals. We’re profitable. We have cash flow, which has allowed us to accumulate more than $15 million cash organically, and we have no debt. We’re more profitable and certainly undervalued when compared with the THC focused cannabis stocks, all of whom say their growth potential is off the charts. We think ours is, too.”
As discussed in our earnings call last week, we continue to raise the bar not just for our company, but the industry as a whole. We appointed Deloitte as our auditors earlier this year and retained special legal counsel to help in our Nasdaq uplist effort, which is a top priority for our company. The company continues to add respected industry leaders to its senior management team. Additionally, CV Sciences has retained other world-class industry experts, including in marketing, sales and e-commerce operations.
CV Sciences pioneered the CBD consumer product industry, and as the regulatory framework emerges, our industry dominance and growth will continue and escalate. We ask that you trust in the long-term vision of this great company, the strong team we have built, and our proven track record of business performance, science-based R&D and regulatory leadership. We believe we are well-positioned to capitalize on the conservatively projected $20 billion plus CBD industry and we look forward to sharing news of future business development successes in the coming months.
Thank you for your continued support.
Sincerely,
Joseph Dowling
Chief Executive Officer